PURPOSEThe TRK inhibitor larotrectinib is US Food and Drug Administration approved for NTRK fusion–positive solid tumors that lack a satisfactory alternative or have progressed after treatment but has not been systematically studied as a frontline therapy …
Christina Curtis, PhD, MSc, on Wednesday discussed processes that drive cancer progression across various disease stages and molecular subtypes.
The combination of revumenib plus decitabine/cedazuridine showed high rates of remission among patients with relapsed/refractory AML with KMT2Ar, NPM1mt, and NUP98r genetic alterations.
Knowing your family health history is important — and could ultimately be life-saving for you or a family member. Kari Thorsen, MS, CGC, is a…
This randomized clinical trial investigates whether a single oral dose of cannabidiol improves scan-related anxiety in women with advanced breast cancer.
A pooled analysis of 9548 HNC cases and 15,783 controls from the International Head and Neck Cancer Epidemiology consortium was conducted to assess the association…
Retrospective analysis results demonstrated that lurbinectedin shows promise as a potential new second-line option for patients with platinum-sensitive small cell lung cancer who experience relapse…
Holiday happenings around Temple Health this year included a festive luncheon attended by members of the Perioperative Care team at Fox Chase Cancer Center.
PURPOSEDespite a universal public health care system, Canadian oncology patients often enroll in patient assistance programs (PAPs) to access oncology drugs that are awaiting funding…
